# Analysis of Potential Cinnamomum zeylanicum Blume Essential Oil Against Alzheimer's Disease: A Molecular Docking Study

by Muhammad Ja'far Shodiq

Submission date: 19-Aug-2023 05:39PM (UTC+0800) Submission ID: 2147913582 File name: 11.\_Analysisis\_of\_Potential.pdf (1.5M) Word count: 5684 Character count: 31960



Jurnal Farmasi dan Ilmu Kefarmasian Indonesia Vol. 10 No. 1 April 2023, 111-125 DOI: 10.20473/jfiki.v10i12023.111-125 Available online at https://e-journal.unair.ac.id/JFIKI/

#### Analysis of Potential *Cinnamomum zeylanicum* Blume Essential Oil Against Alzheimer's Disease: A Molecular Docking Study

Muhammad Ja'far Shodiq<sup>1</sup>, Farmindo Hartono<sup>1</sup>, Siti Khaerunnisa<sup>2\*</sup>, Abdulloh Machin<sup>3</sup> <sup>1</sup>Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

<sup>2</sup>Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

<sup>2</sup>Departement of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia <sup>3</sup>Departement of Neuorology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital, Surabaya, Indonesia

\*Corresponding author: st.khaerunnisa@fk.unair.ac.id

Submitted: 19 November 2022 Accepted: 3 March 2023 Published: 30 April 2023

#### Abstract

**Background:** Alzheimer's Disease (AD) is a neurodegenerative disorder with progressive impairment of behavioural and cognitive functions and the most common cause of dementia. The pathophysiology of AD is associated with low acetylcholine, accumulation of amyloid beta plaque, and neurofibrillary tangles in the brain. Cinnamonum zeylanicum is known to have many medicinal properties, especially neuroprotective effects. Objective: This research was designed to determine the neuroprotective potential of the phytochemicals C. zeylanicum using an in silico study. Methods: There are 5 phytochemicals compounds of C. zeylanicum used in this study. It's qualified for Lipinski's rules of five and can cross blood brain barrier. The protein targets were AChE, BACE1, and GSK-3. Molecular docking and visualization were performed using Avogadro, AutoDock 4.2 PyMol and Biovia Discovery Studio 2019. Results: In silico results show that the main phytochemical compounds of C. zeylanicum Blume essential oil have great potency as an AD drug. The best interaction model of the compound was shown by trans-cinnamyl acetate and coumaric acid. Although the binding energy of the compounds is lower than AD drugs (donepezil, rivastigmine, galantamine), the binding energy is not much different from rivastigmine and galantamine. Conclusion: The phytochemical compounds of C. zeylanicum Blume essential oil have an effect as a neuroprotective agent for AD and should be investigated in future research.

Keywords: Alzheimer's Disease, Cinnamomum zeylanicum, Molecular Docking Study

#### How to cite this article:

Shodiq, M. J., Hartono, F., Khaerunnisa, S. & Machin, A. (2023). Analysis of Potential *Cinnamomum zeylanicum* Blume Essential Oil Against Alzheimer's Disease: A Molecular Docking Study. *Jurnal Farmasi dan Ilmu Kefarmasian Indonesia*, 10(1), 111-125. http://doi.org/10.20473/jfiki.v10i12023.111-125

P-ISSN: 2406-9388 E-ISSN: 2580-8303

#### Jurnal Farmasi dan Ilmu Kefarmasian Indonesia Vol. 10 No. 1 April 2023 112

#### INTRODUCTION

Alzheimer's Disease (AD) known as a neurodegenerative disorder that mostly attacks people over 65 years marked by insidious onset and progressive impairment of behavioral and cognitive functions including memory, comprehension, language, attention, reasoning, and judgment (Cassani et al., 2018; Cortes-Canteli and Iadecola, 2020; Kumar et al., 2022). AD is the supreme cause of dementia worldwide (60-80%) and also causes a decline in cognitive ability (Lucey, 2020; Litke et al., 2021). In 2015, around 46.8 million people worldwide suffered from AD; it's predicted to be 82 million in 2030 and 152 million in 2050. About 10 million new cases of AD are reported yearly worldwide (Cassani et al., 2018; Vinicius et al., 2019). In the Asia-Pacific region, AD is estimated to increase from 23 million in 2015 to 71 million in 2050 (Alzheimer's Disease International and Alzheimer's Australia, 2014). In Indonesia, the prevalence of AD patients was about 1.2 million in 2013, and it was estimated to have a rapid increase to 1.9 million in 2030 and 3.9 million in 2050 (Ong et al., 2021). The cause of this increase is due to increasing life expectancy worldwide. In 2015, life expectancy reached 72 years in Indonesia itself (Kumar et al., 2022). This will have an impact on the health and socio-economic sectors (Ong et al., 2021).

One of the pathophysiologies of AD is cholinergic neuron dysfunction caused by cholinergic toxicity. Overactivity of AChE will cause a significant decrease in ACh levels in the synaptic cleft in the cortex, hippocampus, and amygdala. It will disturb cholinergic neurons involved in brain functions such as learning, memory, attention, response, sleep, and the delivery of sensory information (Kumar et al., 2022; Samanta, Ramesh and Govindaraju, 2022). Accumulation of Aß plaques is also found in AD. This accumulation results in amyloid aggregation that promotes microglial activation and local inflammatory responses and leads to neurotoxicity. Amyloid deposition occurs around the meningeal and cerebral blood vessels and grey matter in AD (Dá Mesquita et al., 2016; Tiwari et al., 2019; Fan et al., 2020; Kumar et al., 2022). The presence of neurofibrillary tangles has been proven to have a relationship with AD. Hyperphosphorylation of the tau protein will form these tangles. The main function of tau protein is to stabilize axonal microtubules in the brain. Neurofibrillary tangles are stored in neurons and occur first in the hippocampus, then they are seen throughout the cerebral cortex (Long and Holtzman, 2019; Tiwari et al., 2019; Kumar et al., 2022). Some drugs that the FDAthe FDA approves approves for AD are donepezil, galantamine, and rivastigmine (Yiannopoulou and Papageorgiou, 2020). However, these drugs have side effects such as gastrointestinal disturbances, dyspepsia, nausea, vomiting, loss of appetite, diarrhea, muscle aches, loss of balance, headache, and hepatotoxicity (Kumar, Chowdhury and Kumar, 2017; Kallel et al., 2019). In recent years, there is many studies to develop new anti-AD drugs with lesser side effects (Kareti and Pharm, 2020);

*C. zeylanicum* Blume is an aromatic plant from Sri Lanka and the Malabar coasts of India. It was usually

us as seasoning in Asian traditional food and herbal medicine in different cultures and systems (Fahad et al., 2018; Kallel et al., 2019). It has many medicinal properties such as anti inflammatory, anti oxidant, analgesic, anti-cancer, anti-diabetic, anti-microbial, cardiovascular protective, 57 cytoprotective, and neuroprotective (Momtaz et al., 2017; Wang et al., 2020). The herbal plants used to treat several diseases have developed rapidly in recent years (Kareti and Pharm, 2020). Plants are considered to be one of the sources of therapeutic active compounds, so this research was conducted to find new anti-AD drugs from herbal plants that might later have fewer side effects. C. zevlanicum Blume essential oil was chosen because it is believed to have a useful neuroprotective effect on AD. In previous studies, C. zeylanicum had anti-alzheimer's activity by inhibiting the nucleation process and the formation of tau filaments (Dhage et al., 2021). Tepe and Ozaslan (2020) reported that C. zeylanicum had AChE inhibitory activity, which plays a role in the pathophysiology of AD. Frydman-Marom et al. (2011) also reported that C. zeylanicum can inhibit Aß plaque accumulation in AD.

#### MATERIAL AND METHODS System Configuration

This molecular docking study used operating Windows 10 OS 32 bit laptop with an Intel Core i3 processor and 2 GB RAM. Applications in silico research include Avogadro, AutoDock 4.2, Biovia Discovery Studio 2019, and PyMol.

#### Ligand and Protein Selection

C. zeylanicum Blume essential oil has the main phytochemical compounds namely cinnamaldehyde, trans-cinnamyl acetate, 1,4-benzene dicarboxylic acid, 1,8-cineole, a-pinene, coumaric acid, and 9octadecenoic acid (Kallel et al., 2019). The compound that is qualified for Lipinski's rule of five and can cross blood-brain barrier (BBB) is used in this molecular docking. The terms of Lipinski's rule of five can be checked through the website http://www.swissadme.ch/index.php. The qualified compounds will be compared with donepezil, galantamine, and rivastigmine, which are some of the FDA-approved drugs for AD (Yiannopoulou and Papageorgiou, 2020). The qualified compounds are cinnamaldehyde, trans-cinnamyl acetate, 1,8-cineole, αpinene, and coumaric acid (Table 1). The 3D structure of the phytochemicals is downloaded from the website https://pubchem.ncbi.nlm.nih.gov and will be used as a ligand. The ligands were docked with the acetylcholinesterase/AChE receptor (PDB ID: 7E3H), β-site APP cleaving enzyme 1/BACE1 (GDP ID: 4DJU), and glycogen synthase kinase-3/GSK-3 (PDB ID: 1Q5K). These receptors play an important role in the pathophysiology of AD (Jagust, 2018). The protein structure was downloaded from the protein data bank (PDB) website http://www.rcsb.org.

#### Ligand Structure Optimization

56 The compounds downloaded in ".sdf" format are optimized using Avogadro software and saved in ".mol2" format. After that, the compounds in ".mol2" format converted to ".pdbqt" format was using AutoDock 4.2 software.

#### **Protein Structure Preparation**

The macromolecular structure of the protein downloaded in ".pdb" format from Protein Data Bank (PDB) was searched for the active site using the BIOVIA Discovery Studio 2019 software. In AChE, BACE1, and GSK-3 proteins, there are two chains, Chain A and B. Then we choose chain A, which is used for docking using AutoDock 4.2 software. Proteins were optimized by adding polar hydrogens, merging non-polar, adding Kollman charges in proteins, and computing gasteiger in native ligands. After that, the receptor is separated from the native ligand and saved in ".pdbqt" format.

#### Grid Box Determination

The size, centre coordinates, and spacing of the grid box are determined by the position of the native ligand using AutoDock 4.2 software. In AChE protein, the native ligand E20 grid was set in 40x40x40 (XYZ) point size, -43.74, 37.597, -30.039 centre coordinates, and 0.375 A spacing. In the BACE1 protein, the native

Table 1. Ligand Structure of Molecular Dockin	Table 1.	Ligand	Structure	of Molecular	Docking
---	----------	--------	-----------	--------------	---------

ligand 0KK grid was set in 40x40x40 (XYZ) point size, 21,029, 10,689, 22,069 centre coordinates, and 0.375 A spacing. In the GSK-3 protein, the native ligand TMU grid was set in 40x40x40 (XYZ) point size, 23,148, 22.189, 8,978 centre coordinates, and 0.375 A spacing.

#### Molecular Docking

Proteins and ligands that have been prepared and grid boxes that have been determined are saved in ".gpf" format, and molecular docking is carried out with AutoDock 4.2 software. The ligand conformation output was analyzed using the Lamarckian Genetic Algorithm. Compounds that have the lowest bond energy ( $\Delta G$ ) show strong bonds and favourable conformations for ligand and protein interactions. After that, the results obtained in ".dlg" format are reopened using AutoDock 4.2 software to view the ligand bonds with amino acids and saved in ".pdb" format. The molecular docking results were visualized using the PyMol and BIOVIA Discover Studio 2019 software (Khaerunnisa, Suhartati and Awaluddin, 2020).

Ligand	Molecular Formula	PubChem CID	Molecular Structure
	C. zeylanicum blun	ne essential oil	
Cinnamaldehyde	$C_9H_8O$	637511	С
Trans-cinnamyl acetate	$C_{11}H_{12}O_2$	5282110	
1,8-cineole	$C_{10}H_{18}O$	2758	×
α-pinene	$C_{10}H_{16}$	6654	
Coumaric acid	$C_9H_8O_3$	637542	ОН
	Alzheimer's di	sease drug	
Donepezil	C <sub>24</sub> H <sub>29</sub> NO <sub>3</sub>	3152	e por con co
Galantamine	$C_{17}H_{21}NO_3$	9651	H <sub>3</sub> C <sup>-O</sup> H H <sub>OH</sub> H

Jurnal Farmasi dan Ilmu Kefarmasian Indonesia Vol. 10 No. 1 April 2023 114

Rivastigmine

 $C_{14}H_{22}N_2O_2$ 

77991

#### RESULTS AND DISCUSSION

C. zeylanicum Blume essential oil has 23 phytochemical compounds which represent at 99.39% of total essential oil. The main phytochemical compounds were cinnamaldehyde, *trans*-cinnamyl acetate, 1,4-benzene dicarboxylic acid, 1,8-cineole,  $\alpha$ pinene, coumaric acid, and 9-octadecenoic acid (Kallel *et al.*, 2019). Phytochemicals were screened before docking. Five phytochemical compounds were selected for molecular docking analysis. Due to Lipinski's rule of five, all of the ligands have zero violations, but 1,4benzene dicarboxylic acid and 9-Octadecenoic acid can't cross the BBB, so the ligands are excluded (Table 2). Lipinski's rule of five terms consists of molecular weight <500 Da, log P <5, H-bond donor <5, and Hbond acceptor <10. Lipinski's rule of five can be used to classify the phytochemicals that may be effective in being used as drugs (Lipinski *et al.*, 2001). The compound must cross the BBB because the target receptor being inhibited is located in the brain (Pardridge, 2020).

Table 2. ADME Analysis of C. zevlanicum Blume Essen	tial Oil Compound
---	-------------------

	Lipinski's Rule of Five					BBB
Phytochemical Compound	Molecular Weight	Log P	H-bond donor	H-bond acceptor	Violations	Permeant
Cinnamaldehyde	132,16	1,97	0	1	0	Yes
Trans-cinnamyl acetate	176,21	2,33	0	2	0	Yes
1,4-benzenedicarboxylic acid	166,13	1,13	2	4	0	No
1,8-cineole	154,25	2,67	0	1	0	Yes
α-pinene	136,23	3,44	0	0	0	Yes
Coumaric acid	164,16	1,26	2	3	0	Yes
9-Octadecenoic acid	282,46	5,71	1	2	0	No

AChE (PDB ID: 7E3H) is a cholinergic enzyme primarily found at postsynaptic neuromuscular junctions (NMJ). AChE immediately breaks down acetylcholine into acetic acid and choline in NMJ. AChE plays a critical role in AD (Trang and Khandhar, 2022). 7E3H has a total structure Weight of 120.37 kDa, an Atom Count of 8437, a Modeled Residue Count of 1054, a Deposited Residue Count of 1080, and one Unique protein chain. This receptor has a native ligand E20 that binds to 14 active site amino acids namely TYR072, ASP074, GLU202, TRP286, VAL294, PHE295, PHE338, TYR341, SER293, TRP086, GLY121, TYR124, TYR337, and HIS447. BACE1 (PDB ID: 4DJU) is a  $\beta$ -secretase involved in the  $\beta$ amyloid peptide, a dominant component in AD (Gnanaraj et al., 2022). 4DJU has a total structure Weight of 93.33 kDa, an Atom Count of 7068, a Modeled Residue Count of 779, a Deposited Residue Count of 828, and one Unique protein chain. This receptor has a native ligand 0KK that binds to 13 active site amino acids namely LEU091, ASP093, GLY095, SER096, VAL130, TYR132, TRP137, PHE169, TRP176, ILE179, ASP289, GLY291, and THR292 (Cumming et al., 2012). GSK3 (PDB ID: 1Q5K) is a serine/threonine protein kinase that phosphorylates Tau protein, whose expression is associated with AD (Gnanaraj et al., 2022). 1Q5K has a total structure Weight of 92.85 kDa, an Atom Count of 5930, a Modeled Residue Count of 689, a Deposited Residue Count of 828, and one Unique protein chain. This receptor has a native ligand TMU that binds to 12 active

site amino acids, namely VAL061, ILE062, VAL070, ALA083, VAL135, PRO136, LEU132, LEU188, ASP133, TYR134, ARG141, and CYS199 (Bhat *et al.*, 2003). Table 3 also visualizes the 3D structure of each receptor at 2.45, 1.80, and 1.94 Å X-ray diffraction resolutions.

Based on the results of molecular docking, the phytochemical of C. zeylanicum Blume essential oil that has the strongest binding energy to the AChE receptor is trans-cinnamyl acetate ( $\Delta G$ : -6.21 kcal/mol) with an inhibition constant of 27.84 µM. The other compounds, α-pinene, 1.8-cineole, acid. coumaric and cinnamaldehyde had binding energies of -5.96, -5.86, -5.76, and -5.50 kcal/mol with inhibition constants of 43.49, 50.56, 60.95, and 92.75 µM. In the AD drug, donepezil, galantamine, and rivastigmine had binding energies of -11.04, -8.05, and -7.29 kcal/mol with inhibition constants of 8.15 nM,  $1.26 \,\mu$ M, and  $4.52 \,\mu$ M. At the BACE1 receptor, the phytochemical of C. zeylanicum Blume essential oil with the strongest binding energy is trans-cinnamyl acetate (ΔG: -5.16 kcal/mol) with an inhibitory constant of 164.04 µM. The other compounds, cinnamaldehyde, coumaric acid,  $\alpha$ pinene, and 1,8-cineole have binding energies of -4.62, -4.51, -4.43, and -4.41 kcal/mol with inhibition constants of 408.29, 496.02, 567.62, and 583.24 µM. Meanwhile, donepezil, galantamine, and rivastigmine had binding energies of -8.50, -6.08, and -5.89 kcal/mol with inhibition constants of 588.62 nM, 34.99 µM, and 47.78 µM. At the GSK-3 receptor, the phytochemical of C. zeylanicum Blume essential oil with the strongest binding energy is coumaric acid ( $\Delta$ G: -5.61 kcal/mol) with an inhibition constant of 77.41  $\mu$ M. Other compounds, *trans*-cinnamyl acetate, 1,8-cineole, cinnamaldehyde, and  $\alpha$ -pinene have binding energies of -5.47, -4.93, -4.92, and -4.83 kcal/mol with inhibition

constants of 97.51, 245.32, 248.03, and 287.66  $\mu$ M. Meanwhile, donepezil, galantamine, and rivastigmine had binding energies of -8.53, -6.29, and -6.22 kcal/mol with inhibition constants of 562.75 nM, 24.71  $\mu$ M, and 27.74  $\mu$ M (Table 4).

Protein Target	PDB ID	Active Site	3D Structure
AChE (Acetylcholinesterase) Crystal structure of human acetylcholinesterase in complex with donepezil	7E3H	TYR072, ASP074, TRP086, GLY121, TYR124, GLU202, TRP286, SER293, VAL294, PHE295, TYR337, PHE338, TYR341, HIS447	
62 BACE1 (β-site APP Cleaving Enzyme 1) Structure of BACE bound to 2- imino-3-methyl-5,5- diphenylimidazolidin-4-one	4DJU	LEU091, ASP093, GLY095, SER096, VAL130, TYR132, TRP137, PHE169, TRP176, ILE179, ASP289, GLY291, THR292	
GSK-3 (Glycogen Synthase Kinase-3) crystal structure of glycogen synthase kinase 3 in complexed with inhibitor	1Q5K	VAL061, ILE062, VAL070, ALA083, LEU132, ASP133, TYR134, VAL135, PRO136, ARG141, LEU188, CYS199	

The molecular docking results are then visualized in Table 5. At the AChE receptor, the phytochemical of *C. zeylanicum* Blume essential oil, cinnamaldehyde binds to 9 amino acids with 7 van der Waals bonds, *trans*-cinnamyl acetate binds to 8 amino acids with 4 van der Waals bonds, 1,8-cineole binds to 8 amino acids with 2 van der Waals bonds,  $\alpha$ -pinene binds to 8 amino acids with 2 van der Waals bonds,  $\alpha$ -pinene binds to 8 amino acids to 12 amino acids with 9 van der Waals bonds, and coumaric acid binds to 12 amino acids with 9 van der Waals bonds. In the AD drug, donepezil binds to 14 amino acids with 6 van der Waals bonds, and rivastigmine binds to 11 amino acids with 5 van der Waals bonds. At the BACE1 receptor, it was found that cinnamaldehyde binds to 11

amino acids with 5 van der Waals bonds, *trans*cinnamyl acetate binds to 10 amino acids with 6 van der Waals bonds, 1,8-cineole binds to 7 amino acids with 2 van der Waals bonds,  $\alpha$ -pinene binds to 7 amino acids with 3 van der Waals bonds, and coumaric acid binds to 10 amino acids with 7 van der Waals bonds. Meanwhile, donepezil binds to 17 amino acids with 11 van der Waals bonds, galantamine binds to 12 amino acids with 6 van der Waals bonds, and rivastigmine binds to 11 amino acids with 1 van der Waals bond. At the GSK-3 receptor, it was found that cinnamaldehyde binds to 12 amino acids with 8 van der Waals bonds, *trans*cinnamyl acetate binds to 14 amino acids with 9 van der Waals bonds, 1,8-cineole binds to 9 amino acids with 3 van der Waals bonds,  $\alpha$ -pinene binds to 11 amino acids with 4 van der Waals bonds, and coumaric acid binds to 11 amino acids with 5 van der Waals bonds. Meanwhile, donepezil binds to 12 amino acids with 6 van der Waals bonds, galantamine binds to 12 amino acids with 7 van der Waals bonds, and rivastigmine binds to 11 amino acids with 5 van der Waals bonds.

	Protein Targets Associated With Alzheimer's Disease						
Lines	AChE		0	BACE1		SK-3	
Ligand	ΔG (kcal/mol)	Ki	ΔG (kcal/mol)	Ki	ΔG (kal/mol)	Ki	
		C. zeylanici	um blume essent	ial oil			
Cinnamaldehyde	-5.50	92.75 μM	-4.62	408.29 µ M	-4.92	248.03 µM	
Trans-cinnamyl acetate	-6.21	27.84 µM	-5.16	164.04 µ M	-5.47	97.51 μM	
1,8-cineole	-5.86	50.56 µ M	-4.41	583.24 µ M	-4.93	245.32 µM	
α-pinene	-5.96	43.49 µM	-4.43	567.62 µ M	-4.83	287.66 µM	
Coumaric acid	-5.76	60.95 µM	-4.51	496.02 µ M	-5.61	77.41 µM	
		Alzheir	ner's disease dru	ıg			
Donepezil	-11.04	8.15 nM	-8.50	588.62 nM	-8.53	562.75 nM	
Galantamine	-8.05	1.26 µM	-6.08	34.99 µM	-6.29	24.71 µM	
Rivastigmine	-7.29	4.52 µM	-5.89	47.78 µM	-6.22	27.74 µM	

Cinnamaldehyde is a natural flavonoid and derivative compound of the volatile chemical aldehyde that gives cinnamon its flavour and aroma. Cinnamaldehyde is the main phytochemical compound of C. zeylanicum Blume essential oil (about 90%) (National Center for Biotechnology Information, 2022c). It has many pharmacological activities, including antiinflammatory, antimicrobial, anti-cancer, antihyperglycemic, and neuroprotection (Zhang et al., 2015). Trans-cinnamyl acetate is an acetate ester produced from the condensation of cinnamyl alcohol and acetic acid (National Center for Biotechnology Information, 2022b). Its pharmacological properties include anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, anti-anxiety, antidepressant, and neuroprotection (Rao and Gan, 2014). Cinnamaldehyde and trans-cinnamyl acetate have neuroprotection functions that can be used for preventive and therapeutic nervous system diseases (Zhang et al., 2015). 1,8-Cineole (eucalyptol) is an achiral aromatic component of many plants, including C. Zeylanicum (National Center for Biotechnology Information, 2022a). 1,8-Cineole has potential pharmacological properties such as anti-inflammatory, antioxidative, anti-cancer, and neuroprotection. 1,8-Cineole was used to treat nervous system disease (Cai et al., 2020). a-pinene is an organic compound of the polyphenolic group terpene and a component of many aromatic, dietary plants, such as C. Zeylanicum (National Center for Biotechnology Information, 2022e). a-pinene has pharmacological properties such as antinociceptive and antioxidant. a-pinene has a strong anti-inflammatory effect in some pathological


conditions.  $\alpha$ -pinene also has neuroprotective effect, and it's capable of restoring BBB function and attenuating sensorimotor dysfunctions (Khoshnazar, Parvardeh and Bigdeli, 2020). Coumaric acid is derivative of cinnamic acid mono-hydroxylated at the phenyl group. It is the most abundant isoform and is found at significant levels in many plants, including C. Zeylanicum (National Center for Biotechnology Information, 2022d). Coumaric acid has many pharmacological activities, including anti-inflammatory, antidiabetes, antibacterial, hepatoprotective, nephronprotective, and neuroprotective. It has high free radical scavenging. Coumaric acid has potential preventive and therapeutic value for memory-impaired individuals, especially agerelated memory-impaired in older people (Ferreira et al., 2018).


C. zeylanicum Blume essential oil, with its main phytochemical compound cinnamaldehyde, transcinnamyl acetate, 1,8-cineole,  $\alpha$ -pinene, and coumaric acid, has a neuroprotective potential function. It was shown from molecular docking that it can inhibit the receptors AChE, BACE, and GSK-3. It prevents acetylcholinesterase from breaking down acetylcholine. The higher concentration of acetylcholine leads to better communication between nerve cells in the brain and may ease some symptoms of AD (Kumar et al., 2022). C. zeylanicum Blume essential oil also prevents the accumulation and formation of AB plaques and neurofibrillary tangles in neurons from preventing neurotoxicity and worsening AD. It has an antioxidant, neurostimulator function, and prevents neuronal loss (Hamidpour et al., 2015; Momtaz et al., 2017; Hajinejad et al., 2020).

Table 5. Visualization of Ligands with Th	Protein Target
---	----------------


Protein	Ligand	Amino Acid Bond	2D Visualization	3D Visualization	
---------	--------	--------------------	------------------	------------------	--


#### Table 4. Molecular Docking Results of Ligands with The Protein Target













Jurnal Farmasi dan Ilmu Kefarmasian Indonesia Vol. 10 No. 1 April 2023 121





#### CONCLUSION

Molecular Docking of main phytochemical compounds of *C. zeylanicum* Blume essential oil has potency as Alzheimer's disease drug. These findings implicated that compounds could actively block the acetylcholinesterase, glycogen synthase kinase-3, and  $\beta$  site APP cleaving enzyme 1 activity. The best interaction model of the compound was shown by *trans*-cinnamyl acetate and coumaric acid. The binding energy of the compounds is lower than AD drugs (donepezil,

rivastigmine, galantamine), but it is not significantly different from AD drugs to inhibit the receptors. Our study can be used as the basis for conducting further research. In vitro studies, in vivo studies, pharmacokinetics and bioavailability of compounds, compound structures, and structure-activity relationships are needed to ensure the potency of *C. zeylanicum* Blume essential oil as an AD drug.

#### ACKNOWLEDGMENTS

All authors contributed to this study. This Study was supported by the Departemen of Physiology and Medical Biochemistry and Department of Neurology, Faculty of Medicine, Universitas Airlangga, Indonesia.

#### CONFLICT OF INTEREST

There are no potential conflicts of interest to declare in this study.

#### **REFERENCES**

- Alzheimer's Disease International and Alzheimer's Australia (2014) Dementia in the Asia Pacific Region, Alzheimer's Disease International. London: Alzheimer'ss Disease International. Available at: https://www.alz.co.uk/dementiain-the-asia-pacific.
- Bhat, R. et al. (2003) 'Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418', Journal of Biological Chemistry, 278(46), pp. 45937–45945. doi: 10.1074/jbc.M306268200.
- Cai, Z. M. et al. (2020) '1,8-Cineole: a review of source, biological activities, and application', Journal of Asian Natural Products Research. Taylor & Francis. doi: 10.1080/10286020.2020.1839432.
- Cassani, R. et al. (2018) 'Systematic review on restingstate EEG for Alzheimer's disease diagnosis and progression assessment', *Disease Markers*, 2018, pp. 1–26. doi: 10.1155/2018/5174815.
- Cortes-Canteli, M. and Iadecola, C. (2020) 'Alzheimer's Disease and Vascular Aging', *Journal of the American College of Cardiology*, 75(8), pp. 942–951. doi: 10.1016/j.jacc.2019.10.062.
- Cumming, J. N. et al. (2012) 'Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor', *Bioorganic and Medicinal Chemistry Letters*. Elsevier Ltd, 22, pp. 2444–2449. doi: 10.1016/j.bmcl.2012.02.013.
- Dá Mesquita, S. *et al.* (2016) 'Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system', *Neuroscience and Biobehavioral Reviews*. Elsevier Ltd. doi: 10.1016/j.neubiorev.2016.06.014.
- Dhage, P. A. *et al.* (2021) 'Leveraging hallmark Alzheimer's molecular targets using phytoconstituents: Current perspective and

P-ISSN: 2406-9388 E-ISSN: 2580-8303 emerging trends', *Biomedicine and Pharmacotherapy*. Elsevier Masson SAS, 139, pp. 1–16. doi: 10.1016/j.biopha.2021.111634.

- Fahad, M. et al. (2018) 'Medicinal and pharmacological role of traditional Asian Food condiment: Cinnamomum zeylanicum Blume', International Journal of Advances in Pharmacy Medicine and Bioallied Sciences, 6(1), pp. 22–30. Available at: http://biomedjournal.com/medicinal-andpharmacological-role-of-traditional-asian-foodcondiment-cinnamomum-zeylanicum-blume/.
- Fan, L. et al. (2020) 'New Insights Into the Pathogenesis of Alzheimer's Disease', Frontiers in Neurology, 10, pp. 1–12. doi: 10.3389/fneur.2019.01312.
- Ferreira, P. S. et al. (2018) 'A Review of Analytical Methods for p-Coumaric Acid in Plant-Based Products, Beverages, and Biological Matrices', Critical Reviews in Analytical Chemistry. Taylor & Francis. doi: 10.1080/10408347.2018.1459173.
- Frydman-Marom, A. et al. (2011) 'Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models', PLoS ONE, 6(1), pp. 1–11. doi: 10.1371/journal.pone.0016564.
- Gnanaraj, C. et al. (2022) 'In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy', *Molecules*, 27. doi: 10.3390/molecules27092834.
- Hajinejad, M. et al. (2020) 'Natural Cinnamaldehyde and Its Derivatives Ameliorate Neuroinflammatory Pathways in Neurodegenerative Diseases', BioMed Research International. doi: 10.1155/2020/1034325.
- Hamidpour, R. et al. (2015) 'Cinnamon from the selection of traditional applications to its novel effects on the inhibition of angiogenesis in cancer cells and prevention of Alzheimer's disease, and a series of functions such as antioxidant, anticholesterol, antidiabetes, antibacteri', Journal of Traditional and Complementary Medicine, 5, pp. 66–70. doi: 10.1016/j.jtcme.2014.11.008.
- Jagust, W. (2018) 'Imaging the evolution and pathophysiology of Alzheimer disease', *Nature Reviews Neuroscience*. Springer US, 19, pp. 687–700. doi: 10.1038/s41583-018-0067-3.
- Kallel, I. et al. (2019) 'Optimization of Cinnamon (Cinnamomum zeylanicum Blume) Essential Oil Extraction: Evaluation of Antioxidant and Antiproliferative Effects', Evidence-based Complementary and Alternative Medicine. Hindawi, 2019. doi: 10.1155/2019/6498347.
- Kareti, S. R. and Pharm, S. M. (2020) 'In Silico Molecular Docking Analysis of Potential Anti-Alzheimer's Compounds Present in Chloroform Extract of Carissa carandas Leaf Using Gas Chromatography MS/MS', Current Therapeutic

Research. Elsevier Inc., 93. doi: 10.1016/j.curtheres.2020.100615.

- Khaerunnisa, S., Suhartati and Awaluddin, R. (2020) *Penelitian in silico untuk pemula*. Surabaya: Airlangga University Press.
- Khoshnazar, M., Parvardeh, S. and Bigdeli, M. R. (2020) 'Alpha-pinene exerts neuroprotective effects via anti-inflammatory and anti-apoptotic mechanisms in a rat model of focal cerebral ischemia-reperfusion', *Journal of Stroke and Cerebrovascular Diseases*. Elsevier Inc., 29(8). doi:

10.1016/j.jstrokecerebrovasdis.2020.104977.

- Kumar, A. et al. (2022) 'Alzheimer Disease', in In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK4999 22/.
- Kumar, Shivani, Chowdhury, S. and Kumar, Suresh (2017) 'In silico repurposing of antipsychotic drugs for Alzheimer's disease', *BMC Neuroscience*. BioMed Central, 18(76), pp. 1– 16. doi: 10.1186/s12868-017-0394-8.
- Lipinski, C. A. *et al.* (2001) 'Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings', 46, pp. 3–26. Available at: https://pubmed.ncbi.nlm.nih.gov/11259830/.
- Litke, R. et al. (2021) 'Modifiable Risk Factors in Alzheimer Disease and Related Dementias: A Review', Clinical Therapeutics. Elsevier Inc., 43(6), pp. 953–965. doi: 10.1016/j.clinthera.2021.05.006.
- Long, J. M. and Holtzman, D. M. (2019) 'Alzheimer Disease: An Update on Pathobiology and Treatment Strategies', *Cell*. Elsevier Inc., 179(3), pp. 312–339. doi: 10.1016/j.cell.2019.09.001.
- Lucey, B. P. (2020) 'It's complicated: The relationship between sleep and Alzheimer's disease in humans', *Neurobiology of Disease*. Elsevier, 144, pp. 1–8. doi: 10.1016/j.nbd.2020.105031.
- Momtaz, S. et al. (2017) 'Cinnamon, a promising prospect towards Alzheimer's disease', *Pharmacological Research*. Elsevier Ltd. doi: 10.1016/j.phrs.2017.12.011.
- National Center for Biotechnology Information (2022a) 'PubChem Compound Summary for CID 2758, Eucalyptol'. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Eu calyptol.
- National Center for Biotechnology Information (2022b) 'PubChem Compound Summary for CID 5282110, Cinnamyl acetate'. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Ci nnamyl-acetate.
- National Center for Biotechnology Information (2022c) 'PubChem Compound Summary for CID 637511, Cinnamaldehyde'. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Ci nnamaldehyde.

P-ISSN: 2406-9388 E-ISSN: 2580-8303

- National Center for Biotechnology Information (2022d) 'PubChem Compound Summary for CID 637542, 4-Hydroxycinnamic acid'. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/4-Hydroxycinnamic-acid.
- National Center for Biotechnology Information (2022e) 'PubChem Compound Summary for CID 6654, alpha-Pinene'. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/al pha-Pinene.
- Ong, P. A. et al. (2021) 'Dementia Prevalence, Comorbidities, and Lifestyle Among Jatinangor Elders', Frontiers in Neurology, 12. doi: 10.3389/fneur.2021.643480.
- Pardridge, W. M. (2020) 'Treatment of alzheimer's disease and blood-brain barrier drug delivery', *Pharmaceuticals*, 13, pp. 1–25. doi: 10.3390/ph13110394.
- Rao, P. V. and Gan, S. H. (2014) 'Cinnamon: A multifaceted medicinal plant', *Evidence-based Complementary and Alternative Medicine*, pp. 1–12. doi: 10.1155/2014/642942.
- Samanta, S., Ramesh, M. and Govindaraju, H. (2022) 'Chapter 1: Alzheimer's is a Multifactorial Disease', in Alzheimer's Disease: Recent Findings in Pathophysiology, Diagnostic and Therapeutic Modalities, pp. 1–34. doi: 10.1039/9781839162732-00001.
- Tepe, A. S. and Ozaslan, M. (2020) 'Anti-Alzheimer, anti-diabetic, skin-whitening, and antioxidant activities of the essential oil of Cinnamomum zeylanicum', *Industrial Crops and Products*. Elsevier, 145, pp. 1–8. doi: 10.1016/j.indcrop.2019.112069.
- Tiwari, S. et al. (2019) 'Alzheimer 's disease: pathogenesis, diagnostics and therapeutics', *International Journal of Nanomedicine*, Jul 2019(14), pp. 5541–5554. doi: 10.2147/IJN.S200490.
- Trang, A. and Khandhar, P. B. (2022) 'Physiology, Acetylcholinesterase', in *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK5397 35/.
- Vinicius, M. et al. (2019) 'Alzheimer's disease: risk factors and potentially protective measures', *Journal of Biomedical Scienceedical Science*. Journal of Biomedical Science, 26(33), pp. 1–11. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C6507104/.
- Wang, J. et al. (2020) 'Traditional uses, phytochemistry and pharmacological activities of the genus Cinnamomum (Lauraceae): A review', *Fitoterapia*. Elsevier, 146. doi: 10.1016/j.fitote.2020.104675.
- Yiannopoulou, K. G. and Papageorgiou, S. G. (2020) 'Current and Future Treatments in Alzheimer Disease: An Update', *Journal of Central Nervous System Disease*, 12, pp. 1–12. doi:

Jurnal Farmasi dan Ilmu Kefarmasian Indonesia Vol. 10 No. 1 April 2023 125


#### 10.1177/1179573520907397.

Zhang, L. et al. (2015) 'Research progress of transcinnamaldehyde pharmacological effects', *China Journal of Chinese Materia Medica*, 40(23), pp. 4568–4572. Available at: https://pubmed.ncbi.nlm.nih.gov/27141665/.

P-ISSN: 2406-9388 E-ISSN: 2580-8303

## Analysis of Potential Cinnamomum zeylanicum Blume Essential Oil Against Alzheimer's Disease: A Molecular Docking Study

ORIGINALITY REPORT



4

Yi Liang Lo, Shi-Hui Cheng. "Chapter 7 Iron and Alzheimer's Disease", Springer Science and Business Media LLC, 2023 Publication	<1%
www.frontiersin.org	<1%
www.hindawi.com	<1%
Submitted to Adtalem Global Education Student Paper	<1%
Submitted to Taylor's Education Group	<1%
zafarchemicals.com	<1%
Kolade O Faloye, Shafi Mahmud, Emmanuel G Fakola, Yemisi M Oyetunde et al. " Revealing the Acetylcholinesterase Inhibitory Potential of and Its Phytoconstituents: In Vitro and in Silico Approach ", Bioinformatics and Biology Insights, 2022 Publication	<1%
	and Alzheimer's Disease", Springer Science and Business Media LLC, 2023 Publication           www.frontiersin.org Internet Source           www.hindawi.com Internet Source           Submitted to Adtalem Global Education Student Paper           Submitted to Taylor's Education Group Student Paper           Zafarchemicals.com Internet Source           Kolade O Faloye, Shafi Mahmud, Emmanuel G Fakola, Yemisi M Oyetunde et al. " Revealing the Acetylcholinesterase Inhibitory Potential of and Its Phytoconstituents: In Vitro and in Silico Approach ", Bioinformatics and Biology Insights, 2022



<1%

13	Paula Scanavez Ferreira, Francesca Damiani Victorelli, Bruno Fonseca-Santos, Marlus Chorilli. " A Review of Analytical Methods for - Coumaric Acid in Plant-Based Products, Beverages, and Biological Matrices ", Critical Reviews in Analytical Chemistry, 2018 Publication	<1%
14	Submitted to University of Alabama at Birmingham Student Paper	<1%
15	cansarblack.icr.ac.uk Internet Source	<1%
16	Submitted to dixons6a Student Paper	<1%
17	researchonline.jcu.edu.au	<1%
18	Christian Bailly, Gérard Vergoten. "Molecular docking study of xylogranatins binding to glycogen synthase kinase-3β", Digital Chinese Medicine, 2022 Publication	<1 %
19	Submitted to Kingston University Student Paper	<1%
20	discovery.ucl.ac.uk Internet Source	<1%

21	Kafeel A Khan, Nitesh Kumar, Pawan G Nayak, Madhavan Nampoothiri et al. "Impact of caffeic acid on aluminium chloride-induced dementia in rats", Journal of Pharmacy and Pharmacology, 2013	<1%
22	Paulus Anam Ong, Febby Rosa Annisafitrie, Novita Purnamasari, Chandra Calista, Noveline Sagita, Yulia Sofiatin, Yustiani Dikot. "Dementia Prevalence, Comorbidities, and Lifestyle Among Jatinangor Elders", Frontiers in Neurology, 2021 Publication	<1%
23	Submitted to University of Greenwich Student Paper	<1%
24	e-space.mmu.ac.uk Internet Source	<1%
25	spaj.ukm.my Internet Source	<1%
26	Jian Ju, Mozaniel Santana de Oliveira, Yu Qiao. "Cinnamon: A Medicinal Plant and A Functional Food Systems", Springer Science and Business Media LLC, 2023 Publication	<1%
27	Neha Singh, Meenakshi Garg, Priyanka Prajapati, Priyanka Kumari Singh, Rajni Chopra, Anita Kumari, Avneesh Mittal.	<1%

# "Adaptogenic property of Asparagus racemosus: Future trends and prospects",

# Heliyon, 2023

Publication

28	www.cb.cs.titech.ac.jp	<1%
29	www.semanticscholar.org	<1%
30	ikee.lib.auth.gr Internet Source	<1%
31	pagepress.org Internet Source	<1%
32	www.researchsquare.com	<1%
33	Submitted to Brigham Young University Student Paper	<1%
34	Mita Shikder, Kazi Ahsan Ahmed, Abu Tayab Moin, Rajesh B. Patil et al. "Repurposing Remdesivir for COVID-19: Computational Drug Design Targeting SARS-CoV-2 RNA Polymerase and Main Protease using Molecular Dynamics Approach", Cold Spring Harbor Laboratory, 2023 Publication	<1%
35	Submitted to Nanyang Polytechnic	<1%

Student Paper

35

36	Neeraj Verma, Siddharth Manvati, Pawan Dhar. "Harnessing Escherichia coli Dark Genome to Produce Anti-Alzheimer Peptides", Cold Spring Harbor Laboratory, 2023 Publication	<1%
37	Somayyeh Hatami Nemati, Mohammad Reza Bigdeli, Fatemeh Mortazavi Moghadam, Kazem Sharifi. "Neuroprotective effects of niosomes loaded with thymoquinone in the cerebral ischemia model of male Wistar rats", Nanomedicine: Nanotechnology, Biology and Medicine, 2022 Publication	<1%
38	Tayebeh Noori, Ahmad Reza Dehpour, Antoni Sureda, Eduardo Sobarzo-Sanchez, Samira Shirooie. "Role of natural products for the treatment of Alzheimer's disease", European Journal of Pharmacology, 2021 Publication	<1%
39	<b>journaljpri.com</b> Internet Source	<1%
40	opus.bibliothek.uni-wuerzburg.de	<1%
41	Mahdieh Khoshnazar, Siavash Parvardeh, Mohammad Reza Bigdeli. "Alpha-pinene exerts neuroprotective effects via anti- inflammatory and anti-apoptotic mechanisms in a rat model of focal cerebral ischemia-	<1%

reperfusion", Journal of Stroke and Cerebrovascular Diseases, 2020 Publication

42	Neuhaus, F.C "Role of the omega loop in specificity determination in subsite 2 of the d- alanine:D-alanine (d-lactate) ligase from Leuconostoc mesenteroides: A molecular docking study", Journal of Molecular Graphics and Modelling, 201109 Publication	<1%
43	Prakashkumar Nallasamy, Beema shafreen Rajamohamed, Jeyakanthan Jeyaraman, Brindhadevi Kathirvel, Suganthy Natarajan. "Regenerative marine waste towards CaCO3 nanoformulation for Alzheimer's therapy", Environmental Research, 2023 Publication	<1%
44	Submitted to Staffordshire University Student Paper	<1%
45	pastebin.com Internet Source	<1%
46	theses.hal.science	<1%
47	"Anti-Parkinson's evaluation of Brassica juncea leaf extract and underlying mechanism of its phytochemicals", Frontiers in Bioscience- Landmark, 2021	<1%

Publication

48	Begüm Nurpelin Sağlık, Serkan Levent, Derya Osmaniye, Asaf Evrim Evren et al. " Design, Synthesis, and and Approaches of Novel Indanone Derivatives as Multifunctional Anti- Alzheimer Agents ", ACS Omega, 2022 Publication	<1 %
49	Prajakta A. Dhage, Archana A. Sharbidre, Sarada P. Dakua, Shidin Balakrishnan. "Leveraging hallmark Alzheimer's molecular targets using phytoconstituents: Current perspective and emerging trends", Biomedicine & Pharmacotherapy, 2021 Publication	<1 %
50	dspace.lu.lv Internet Source	<1%
51	japsonline.com Internet Source	<1%
52	<b>jila.colorado.edu</b> Internet Source	<1%
53	mdpi-res.com Internet Source	<1%
54	theecafellc.com Internet Source	<1%
55	worldwidescience.org	<1%

- Fatai Oladunni Balogun, Karishma Singh, Athika Rampadarath, Ayesha Akoonjee, Kayleen Naidoo, Saheed Sabiu.
   "Cheminformatics identification of modulators of key carbohydrate-metabolizing enzymes from C. cujete for type-2 diabetes mellitus intervention", Journal of Diabetes & Metabolic Disorders, 2023 Publication
  - Juan Liu, Wuwen Feng, Cheng Peng. "A Song of Ice and Fire: Cold and Hot Properties of Traditional Chinese Medicines", Frontiers in Pharmacology, 2021 Publication
  - 58

Jun Wang, Benzheng Su, Haiqiang Jiang, Ning Cui, Zongyuan Yu, Yuhan Yang, Yu Sun. "Traditional uses, phytochemistry and pharmacological activities of the genus Cinnamomum (Lauraceae): A review", Fitoterapia, 2020 Publication

59 Libo Hua, Farah Anjum, Alaa Shafie, Amal Adnan Ashour et al. "Identifying promising GSK3β inhibitors for cancer management: a computational pipeline combining virtual screening and molecular dynamics simulations", Frontiers in Chemistry, 2023 Publication

<1%

<1 %

<1%

Lihu Zhang, Dongdong Li, Fuliang Cao, Wei
Xiao, Linguo Zhao, Gang Ding, Zhen zhong
Wang. "Identification of Human
Acetylcholinesterase Inhibitors from the
Constituents of EGb761 by Modeling Docking
and Molecular Dynamics Simulations",
Combinatorial Chemistry & High Throughput
Screening, 2018
Publication

Pablo Rayff da Silva, Jéssica Cabral de Andrade, Natália Ferreira de Sousa, Anne Caroline Ribeiro Portela et al. "Computational Studies Applied to Linalool and Citronellal Derivatives Against Alzheimer's and Parkinson's Disorders: A Review with Experimental Approach", Current Neuropharmacology, 2023 Publication

62

60

Yu-Sen Wang, Corey Strickland, Johannes H. Voigt, Matthew E. Kennedy et al. "Application of Fragment-Based NMR Screening, X-ray Crystallography, Structure-Based Design, and Focused Chemical Library Design to Identify Novel μM Leads for the Development of nM BACE-1 (β-Site APP Cleaving Enzyme 1) Inhibitors", Journal of Medicinal Chemistry, 2010 Publication <1%

<1%

<1 %



Exclude quotes	Off	Exclude matches	Off
Exclude bibliography	On		

### Analysis of Potential Cinnamomum zeylanicum Blume Essential Oil Against Alzheimer's Disease: A Molecular Docking Study

GRADEMARK REPORT	
FINAL GRADE	GENERAL COMMENTS
/100	
PAGE 1	
PAGE 2	
PAGE 3	
PAGE 4	
PAGE 5	
PAGE 6	
PAGE 7	
PAGE 8	
PAGE 9	
PAGE 10	
PAGE 11	
PAGE 12	
PAGE 13	
PAGE 14	
PAGE 15	